|
Synonyms: evinacumab-dgnb | Evkeeza® | REGN1500
evinacumab is an approved drug (EMA & FDA (2021))
Compound class:
Antibody
Comment: Evinacumab is a fully human monoclonal antibody targeting angiopoietin-like 3 (ANGPTL3). Due to its role in lipid metabolism, ANGPTL3 is being investigated as a potential molecular target for the treatment of hypertriglyceridemia.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A BLAST search of patented peptide sequences reveals that the heavy chain variable domain of evinacumab is identical to SEQ ID: NO 66 from patent US9018356 B2 [3], and the light chain variable region is identical to SEQ ID: NO 74 from the same patent (this heavy/light chain combination corresponds to antibody identifier H4H1276S). Evinacumab utilises a different molecular mechanism compared to Regeneron's already approved anti-hyperlipidemic drug alirocumab (targets proprotein convertase subtilisin/kexin type 9). |
| References |
|
1. Oike Y, Akao M, Kubota Y, Suda T. (2005)
Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med, 11 (10): 473-9. [PMID:16154386] |
|
2. Shimizugawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, Ueda K, Inaba T, Minekura H, Kohama T et al.. (2002)
ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem, 277 (37): 33742-8. [PMID:12097324] |
|
3. Sleeman MW, Guasrova V, Murphy AJ. (2015)
Anti-ANGPTL3 antibodies and uses thereof. Patent number: US9018356 B2. Assignee: Regeneron Pharmaceuticals, Inc.. Priority date: 17/06/2011. Publication date: 28/04/2015. |
